Reducing Fall Risk Post Hip Fracture in Mild Cognitive Impairment
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Hip Fractures
- Mild Cognitive Impairment
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Usual care vs. Usual Care with ExerciseMasking: Double (Investigator, Outcomes Assessor)Masking Description: Assessor and study investigators are blinded to group allocation of participants. Participant cannot be blinded due to the nature of the intervention.Primary Purpose: Prevention
Participation Requirements
- Age
- Between 65 years and 125 years
- Gender
- Both males and females
Description
Hip fracture is recognized as one of the most serious consequences of osteoporosis, less than half regain pre-fracture independence. 95% of all hip fractures in older adults are due to falls. Thus, reducing fall risk while restoring function post-hip fracture is critical. Many with fall-related hip ...
Hip fracture is recognized as one of the most serious consequences of osteoporosis, less than half regain pre-fracture independence. 95% of all hip fractures in older adults are due to falls. Thus, reducing fall risk while restoring function post-hip fracture is critical. Many with fall-related hip fractures have cognitive impairment and they are less likely to regain pre-fracture level of function than those without cognitive impairment. Cognitive impairment also increase falls risk. It is currently unknown whether exercise is efficacious in reducing fall risk and promoting function among older adults with mild cognitive impairment (MCI) and a fall-related hip fracture. The purpose of this 6-month proof-of-concept RCT is to assess the efficacy of the home-based Otago Exercise Program (OEP) compared with usual care in reducing fall risk among community-dwelling older adults with MCI and a fall-related hip fracture.
Tracking Information
- NCT #
- NCT04748354
- Collaborators
- Amgen
- Investigators
- Principal Investigator: Teresa Liu-Ambrose, PhD University of British Columbia Principal Investigator: Larry Dian, MD University of British Columbia Principal Investigator: Jennifer C Davis, PhD University of British Columbia Principal Investigator: Deborha Jehu, PhD University of British Columbia Principal Investigator: Pierre Guy, MD University of British Columbia
Get Well Soon